Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Precarious future of Affordable Care Act leaves US contraceptive devices market at risk of contraction

Trump and Biden have sharply contrasting policies on female patient accessibility to reproductive healthcare. Trump has repeatedly expressed his mandate to overturn the Affordable Care Act (ACA), which currently covers female contraception to the list of preventative services without patient co-payment, unless an employer objects on religious or moral grounds. The reduced accessibility of contraceptives […]
Read more

COVID-19 caused Fujifilm to boost infectious disease manufacturing contract service deals in 2020

Fujifilm Diosynth Biotechnologies USA Inc., a contract development and manufacturing organization (CDMO), has shown a 200% increase in all deal volume for infectious disease drugs over the last year, says GlobalData, a leading data and analytics company. Sharon Cartic, Associate Director Research and Analysis at GlobalData, comments: “Fujifilm Diosynth Biotechnologies has manufacturing contract service agreements in […]
Read more

Gastric and gastroesophageal adenocarcinoma market set to reach $3.9bn by 2029

The gastric and gastroesophageal adenocarcinoma (G/GEJAC) market is expected to grow from $1.6bn in 2019 to $3.9bn in 2029 across the eight major markets (8MM*) at a moderate compound annual growth rate (CAGR) of 9.3%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Gastric and Gastroesophageal Junction Adenocarcinoma Global Drug Forecast and […]
Read more

Hyperimmune globulin provides tantalizing treatment option in COVID-19, but faces competition from convalescent plasma

Hyperimmune intravenous immunoglobulin (hIVIG), derived from plasma, could improve on efficacy of the Food and Drug Administration’s (FDA) authorized COVID-19 convalescent plasma treatment, but whether it will be clinically significant remains nebulous, based on reporting from the Manasi Vaidya, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. In […]
Read more

Innovate UK prioritizing over 39% of funding to COVID-19 grants demonstrates priority for infectious diseases, says GlobalData

The current COVID-19 pandemic has caused the granting agency Innovate UK to prioritize innovative COVID-19 projects. Infectious disease has become the priority in terms of grant funding for companies, in particular small to mid-size enterprises, says GlobalData, a leading data and analytics company. Innovate UK invested almost £1.5m ($2m) on innovative pharmaceutical research projects in […]
Read more

With US election days away, speed of future COVID-19 therapies and vaccine hang in the balance, says GlobalData

The use of Emergency Use Authorizations (EUA) has been deeply polarizing in the US. With only days left until the presidential election, a growing number of pharmaceutical companies are expected to file for emergency use of their products—both therapeutic and prophylactic—to allow for expedited approval and distribution, according to GlobalData, a leading data and analytics […]
Read more

A Democratic victory will improve access to telemedicine in rural areas

Telemedicine use in the US increased from the low ten thousands to around 1.3 million patients in 2020, representing more than 100-fold increase, according to GlobalData, a leading data and analytics company. The accessibility and practicality the technology has demonstrated during the pandemic – especially in urban areas –  means that it is here to […]
Read more

Governments need to sort permanent legal solution as telemedicine is here to stay post-COVID-19

With over three-quarters* of US and European healthcare professionals saying they will continue using telemedicine after the COVID-19 crisis ends, governments are under pressure to make telemedicine a standard mode of care. Countries will need to establish consistent and clear legal frameworks for this technology in order to make permanent the temporary changes implemented to support […]
Read more

Second wave of COVID-19 vaccines unlikely to be required to improve on protection data of first batch of authorized vaccines

With the US’ Food and Drug Administration’s staging an all-day virtual meeting yesterday (22 October) regarding its planned standards for authorizing a COVID-19 vaccine; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view: “In the event at least one of the COVID-19 vaccine frontrunners is granted an FDA Emergency Use […]
Read more

India’s role in global supply of COVID-19 drugs and vaccines remains crucial despite IPR waiver decision, says GlobalData

Following the news that the US and EU have blocked India’s fight for intellectual property rights (IPR) waiver for COVID-19 drugs; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “India is already at the center stage for the supply of repurposed COVID-19 drugs. Moreover, Indian vaccine players are […]
Read more

Positive data for Amylyx’s AMX0035 strengthen its position to enter ALS market

Following Amylyx’s announcement that AMX0035, its amyotrophic lateral sclerosis (ALS) pipeline drug, showed potential to prolong patient survival in addition to slowing rapid disease progression in the open label extension of Phase II/III clinical trial CENTAUR; Sarah Elsayed, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view on the opportunities and challenges in this market: “The new functional and survival benefits of AMX0035 will significantly strengthen the drug’s position to enter the ALS market over the coming years as a […]
Read more

Future uptake of Opdivo and Yervoy combination in oncology is at risk, says GlobalData

Bristol-Myers Squibb’s (BMS) blockbuster combination of Opdivo and Yervoy is facing increasing scrutiny in various oncology indications as to whether the financial burden and clinical toxicity added by Yervoy is worth it. According to leading data and analytics company GlobalData, clinical trials with Opdivo monotherapy outnumber the trials with Opdivo and Yervoy combination. GlobalData has identified that, out of 782 ongoing clinical trials in oncology that have listed Opdivo, Yervoy, or the combination as a primary intervention, Opdivo monotherapy represents the majority. Specifically, 61% of trials include Opdivo monotherapy, 31% of trials the combination, and only 8% include Yervoy monotherapy. Interestingly, only 20% of these trials are industry-sponsored. Sakis […]
Read more

US 2020 elections to determine the fate of several key reproductive health policies

Reproductive health topics are perhaps some of the most divisive in US politics, with President Donald Trump, and his Democratic opponent, former Vice President Joe Biden, taking vastly different positions on several key issues in this area. Reforms restricting or broadening abortion rights, use of federal funding for abortions, and coverage of contraceptive methods at no out-of-pocket cost, will be influenced by the election outcome. Furthermore, a probable conservative-leaning Supreme Court has triggered […]
Read more
1 … 76 77 78 79 80 … 108